Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024Free cash flow was $141.4 million and $493.1 ...

Lantheus Holdings (NASDAQ: LNTH) held its fourth-quarter and full-year 2024 earnings call on Feb. 26, 2025, highlighting achievements in its radiopharmaceutical portfolio and announcing strategic ...

LNTH READ THE FULL LNTH RESEARCH REPORT Lantheus Holdings, Inc. (NASDAQ:LNTH) reported 2024 financial and operational results on February 26 th , producing sales of over $1 billion for Pylarify during ...

Q4 2024 Earnings Call Transcript February 26, 2025 Operator: Good morning. Welcome to the Lantheus Fourth Quarter and Full ...

Welcome to the Lantheus fourth quarter and full year 2024 conference call. (Operator Instructions) This call is being recorded, and a replay will be available in the Investors section of the company's ...

Reports Q4 revenue $391.1M, consensus $376.18M. “2024 was a groundbreaking year for Lantheus (LNTH), as our radiodiagnostic, PYLARIFY, reached ...

View Our Latest Report on Lantheus Lantheus Stock Performance Shares of Lantheus stock opened at $78.23 on Friday. The firm has a market cap of $5.44 billion, a PE ratio of 13.02 and a beta of 0. ...

BEDFORD, Mass., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight ...

Lantheus is promising up to $1.8 billion in milestone payments to POINT if the two radiotherapeutics get FDA approval and meet commercial objectives, plus royalties on net sales.

Lantheus has filed what it says is the first generic version of Novartis’ big-selling cancer radionuclide therapy Lutathera in the US, used to treat rare neuroendocrine tumours (NETs).

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...